HomeBusiness3 ultra-cheap dividend stocks to buy in December

3 ultra-cheap dividend stocks to buy in December

If you’re concerned about rising stock market valuations or just want some reliable income for your portfolio, now could be an optimal time to invest in dividend stocks, many of which look incredibly cheap. While growth investors have largely looked past dividend stocks this year, the good news is that if you focus on these types of investments now, you won’t have to look far to find good deals.

Three stocks that pay you more than the S&P500 average return of 1.2% and which are traded at cheap valuations Merck (NYSE:MRK), Verizon Communications (NYSE: VZ)and Albertsons Companies (NYSE:ACI). This is why these can be excellent income-generating investments that you can add to your portfolio today.

Start your morning smarter! Wake up with Breakfast news in your inbox every market day. Register for free »

Merck is a leading drug manufacturer that pays an attractive dividend of 3.2%. The share price is down 7% this year as the company has not generated particularly strong growth figures. Investors may also be concerned about what lies ahead. For the full year 2024, Merck expects sales to total about $64 billion, which is about a 7% increase from the $60 billion it posted last year.

While these results aren’t necessarily bad, investors may be more concerned that with its best-selling drug Keytruda losing patent protection later this decade, Merck’s sales could come under pressure in the coming years and its growth rate could be even smaller could be. However, the company has invested in its growth, with the recently approved Winrevair, a treatment for pulmonary arterial hypertension, potentially generating around $4 billion in revenue for Merck in the future. The country also has Gardasil, a vaccine that protects against the human papillomavirus, which could generate $11 billion in sales by 2030.

See also  Why these two billionaire-led crypto plays stand out as buys: Analyst

Merck has big shoes to fill as Keytruda raked in a whopping $25 billion in 2023. However, with a focus on development and growth, there is still time for the healthcare company to diversify its business and develop more drugs. And because the stock is trading at just ten times next year’s estimated forward earnings (based on analyst estimates), investors are getting a big discount to help offset the risk and uncertainty ahead. Merck’s modest payout ratio of 64% also suggests its dividend is not in immediate danger.

One dividend stock I wouldn’t hesitate to pick up today is Verizon. It yields 6.1% and the company has increased its dividend payments for 18 years in a row.

- Advertisement -
RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments